Non-Invasive Imaging Biomarkers to Predict the Hepatopulmonary Shunt Fraction Before Transarterial Radioembolization in Patients with Hepatocellular Carcinoma
Charlie Alexander Hamm,1,2,* Felix Busch,1,3,* Anna Pöhlmann,4 Annabella Shewarega,5 Yubei He,1 Robin Schmidt,1 Han Xu,1 Gero Wieners,1 Bernhard Gebauer,1 Lynn Jeanette Savic1,2 1Department of Radiology, Campus Virchow-Klinikum, Charité – Universitätsmedizin Berlin, Corporate Member...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-01-01
|
| Series: | Journal of Hepatocellular Carcinoma |
| Subjects: | |
| Online Access: | https://www.dovepress.com/non-invasive-imaging-biomarkers-to-predict-the-hepatopulmonary-shunt-f-peer-reviewed-fulltext-article-JHC |
| _version_ | 1797954454886023168 |
|---|---|
| author | Hamm CA Busch F Pöhlmann A Shewarega A He Y Schmidt R Xu H Wieners G Gebauer B Savic LJ |
| author_facet | Hamm CA Busch F Pöhlmann A Shewarega A He Y Schmidt R Xu H Wieners G Gebauer B Savic LJ |
| author_sort | Hamm CA |
| collection | DOAJ |
| description | Charlie Alexander Hamm,1,2,* Felix Busch,1,3,* Anna Pöhlmann,4 Annabella Shewarega,5 Yubei He,1 Robin Schmidt,1 Han Xu,1 Gero Wieners,1 Bernhard Gebauer,1 Lynn Jeanette Savic1,2 1Department of Radiology, Campus Virchow-Klinikum, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität Zu Berlin, Berlin, Germany; 2Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany; 3Department of Anesthesiology, Division of Operative Intensive Care Medicine, Campus Virchow-Klinikum, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany; 4Institute of Biometry and Clinical Epidemiology, Charité – Universitätsmedizin Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Berlin, Germany; 5Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA*These authors contributed equally to this workCorrespondence: Lynn Jeanette Savic, Department of Radiology, Campus Virchow-Klinikum, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany, Email lynn-jeanette.savic@charite.dePurpose: To identify disease-specific profiles comprising patient characteristics and imaging biomarkers on contrast-enhanced (CE)-computed tomography (CT) that enable the non-invasive prediction of the hepatopulmonary shunt fraction (HPSF) in patients with hepatocellular carcinoma (HCC) before resin-based transarterial radioembolization (TARE).Patients and Methods: This institutional review board-approved (EA2/071/19) retrospective study included 56 patients with HCC recommended for TARE. All patients received tri-phasic CE-CT within 6 weeks prior to an angiographic TARE evaluation study using technetium-99m macroaggregated albumin. Imaging biomarkers representative of tumor extent, morphology, and perfusion, as well as disease-specific clinical parameters, were used to perform data-driven variable selection with backward elimination to generate multivariable linear regression models predictive of HPSF. Results were used to create clinically applicable risk scores for patients scheduled for TARE. Additionally, Cox regression was used to identify independent risk factors for poor overall survival (OS).Results: Mean HPSF was 13.11% ± 7.6% (range: 2.8– 35.97%). Index tumor diameter (p = 0.014) or volume (p = 0.034) in combination with index tumor non-rim arterial phase enhancement (APHE) (p < 0.001) and washout (p < 0.001) were identified as significant non-invasive predictors of HPSF on CE-CT. Specifically, the prediction models revealed that the HPSF increased with index lesion diameter or volume and showed higher HPSF if non-rim APHE was present. In contrast, index tumor washout was associated with decreased HPSF levels. Independent risk factors of poorer OS were radiogenomic venous invasion and ascites at baseline.Conclusion: The featured prediction models can be used for the initial non-invasive estimation of HPSF in patients with HCC before TARE to assist in clinical treatment evaluation while potentially sparing ineligible patients from the angiographic shunt evaluation study.Keywords: HCC, TARE, SIRT, liver cancer, contrast-enhanced computed tomography |
| first_indexed | 2024-04-10T23:17:39Z |
| format | Article |
| id | doaj.art-760a8977b4d0496e80ba38e88c850efd |
| institution | Directory Open Access Journal |
| issn | 2253-5969 |
| language | English |
| last_indexed | 2024-04-10T23:17:39Z |
| publishDate | 2023-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Hepatocellular Carcinoma |
| spelling | doaj.art-760a8977b4d0496e80ba38e88c850efd2023-01-12T18:03:06ZengDove Medical PressJournal of Hepatocellular Carcinoma2253-59692023-01-01Volume 10274280958Non-Invasive Imaging Biomarkers to Predict the Hepatopulmonary Shunt Fraction Before Transarterial Radioembolization in Patients with Hepatocellular CarcinomaHamm CABusch FPöhlmann AShewarega AHe YSchmidt RXu HWieners GGebauer BSavic LJCharlie Alexander Hamm,1,2,* Felix Busch,1,3,* Anna Pöhlmann,4 Annabella Shewarega,5 Yubei He,1 Robin Schmidt,1 Han Xu,1 Gero Wieners,1 Bernhard Gebauer,1 Lynn Jeanette Savic1,2 1Department of Radiology, Campus Virchow-Klinikum, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität Zu Berlin, Berlin, Germany; 2Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany; 3Department of Anesthesiology, Division of Operative Intensive Care Medicine, Campus Virchow-Klinikum, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany; 4Institute of Biometry and Clinical Epidemiology, Charité – Universitätsmedizin Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Berlin, Germany; 5Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA*These authors contributed equally to this workCorrespondence: Lynn Jeanette Savic, Department of Radiology, Campus Virchow-Klinikum, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany, Email lynn-jeanette.savic@charite.dePurpose: To identify disease-specific profiles comprising patient characteristics and imaging biomarkers on contrast-enhanced (CE)-computed tomography (CT) that enable the non-invasive prediction of the hepatopulmonary shunt fraction (HPSF) in patients with hepatocellular carcinoma (HCC) before resin-based transarterial radioembolization (TARE).Patients and Methods: This institutional review board-approved (EA2/071/19) retrospective study included 56 patients with HCC recommended for TARE. All patients received tri-phasic CE-CT within 6 weeks prior to an angiographic TARE evaluation study using technetium-99m macroaggregated albumin. Imaging biomarkers representative of tumor extent, morphology, and perfusion, as well as disease-specific clinical parameters, were used to perform data-driven variable selection with backward elimination to generate multivariable linear regression models predictive of HPSF. Results were used to create clinically applicable risk scores for patients scheduled for TARE. Additionally, Cox regression was used to identify independent risk factors for poor overall survival (OS).Results: Mean HPSF was 13.11% ± 7.6% (range: 2.8– 35.97%). Index tumor diameter (p = 0.014) or volume (p = 0.034) in combination with index tumor non-rim arterial phase enhancement (APHE) (p < 0.001) and washout (p < 0.001) were identified as significant non-invasive predictors of HPSF on CE-CT. Specifically, the prediction models revealed that the HPSF increased with index lesion diameter or volume and showed higher HPSF if non-rim APHE was present. In contrast, index tumor washout was associated with decreased HPSF levels. Independent risk factors of poorer OS were radiogenomic venous invasion and ascites at baseline.Conclusion: The featured prediction models can be used for the initial non-invasive estimation of HPSF in patients with HCC before TARE to assist in clinical treatment evaluation while potentially sparing ineligible patients from the angiographic shunt evaluation study.Keywords: HCC, TARE, SIRT, liver cancer, contrast-enhanced computed tomographyhttps://www.dovepress.com/non-invasive-imaging-biomarkers-to-predict-the-hepatopulmonary-shunt-f-peer-reviewed-fulltext-article-JHChcctaresirtliver cancercontrast-enhanced computed tomography |
| spellingShingle | Hamm CA Busch F Pöhlmann A Shewarega A He Y Schmidt R Xu H Wieners G Gebauer B Savic LJ Non-Invasive Imaging Biomarkers to Predict the Hepatopulmonary Shunt Fraction Before Transarterial Radioembolization in Patients with Hepatocellular Carcinoma Journal of Hepatocellular Carcinoma hcc tare sirt liver cancer contrast-enhanced computed tomography |
| title | Non-Invasive Imaging Biomarkers to Predict the Hepatopulmonary Shunt Fraction Before Transarterial Radioembolization in Patients with Hepatocellular Carcinoma |
| title_full | Non-Invasive Imaging Biomarkers to Predict the Hepatopulmonary Shunt Fraction Before Transarterial Radioembolization in Patients with Hepatocellular Carcinoma |
| title_fullStr | Non-Invasive Imaging Biomarkers to Predict the Hepatopulmonary Shunt Fraction Before Transarterial Radioembolization in Patients with Hepatocellular Carcinoma |
| title_full_unstemmed | Non-Invasive Imaging Biomarkers to Predict the Hepatopulmonary Shunt Fraction Before Transarterial Radioembolization in Patients with Hepatocellular Carcinoma |
| title_short | Non-Invasive Imaging Biomarkers to Predict the Hepatopulmonary Shunt Fraction Before Transarterial Radioembolization in Patients with Hepatocellular Carcinoma |
| title_sort | non invasive imaging biomarkers to predict the hepatopulmonary shunt fraction before transarterial radioembolization in patients with hepatocellular carcinoma |
| topic | hcc tare sirt liver cancer contrast-enhanced computed tomography |
| url | https://www.dovepress.com/non-invasive-imaging-biomarkers-to-predict-the-hepatopulmonary-shunt-f-peer-reviewed-fulltext-article-JHC |
| work_keys_str_mv | AT hammca noninvasiveimagingbiomarkerstopredictthehepatopulmonaryshuntfractionbeforetransarterialradioembolizationinpatientswithhepatocellularcarcinoma AT buschf noninvasiveimagingbiomarkerstopredictthehepatopulmonaryshuntfractionbeforetransarterialradioembolizationinpatientswithhepatocellularcarcinoma AT pohlmanna noninvasiveimagingbiomarkerstopredictthehepatopulmonaryshuntfractionbeforetransarterialradioembolizationinpatientswithhepatocellularcarcinoma AT shewaregaa noninvasiveimagingbiomarkerstopredictthehepatopulmonaryshuntfractionbeforetransarterialradioembolizationinpatientswithhepatocellularcarcinoma AT hey noninvasiveimagingbiomarkerstopredictthehepatopulmonaryshuntfractionbeforetransarterialradioembolizationinpatientswithhepatocellularcarcinoma AT schmidtr noninvasiveimagingbiomarkerstopredictthehepatopulmonaryshuntfractionbeforetransarterialradioembolizationinpatientswithhepatocellularcarcinoma AT xuh noninvasiveimagingbiomarkerstopredictthehepatopulmonaryshuntfractionbeforetransarterialradioembolizationinpatientswithhepatocellularcarcinoma AT wienersg noninvasiveimagingbiomarkerstopredictthehepatopulmonaryshuntfractionbeforetransarterialradioembolizationinpatientswithhepatocellularcarcinoma AT gebauerb noninvasiveimagingbiomarkerstopredictthehepatopulmonaryshuntfractionbeforetransarterialradioembolizationinpatientswithhepatocellularcarcinoma AT saviclj noninvasiveimagingbiomarkerstopredictthehepatopulmonaryshuntfractionbeforetransarterialradioembolizationinpatientswithhepatocellularcarcinoma |